申请人:GlaxoSmithKline LLC
公开号:EP3170813A1
公开(公告)日:2017-05-24
The invention relates to benzimidazole derivatives of formula (I) which modulate, notably inhibit the activity or function of the phosphoinositide 3'-OH kinase family (PI3 kinases), suitably PI3Kα, PI3Kδ, PI3Kβ and/or PI3Kγ. The invention further relates to these benzimidazoles for use in the treatment of disease states selected from autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. Especially, the invention relates to PI3Kβ selective benzimidazoles for use in treating cancer.
本发明涉及式(I)的苯并咪唑衍生物,其可调节,特别是抑制磷酸肌醇 3'-OH激酶家族(PI3 激酶),尤其是 PI3Kα、PI3Kδ、PI3Kβ 和/或 PI3Kγ 的活性或功能。本发明进一步涉及这些苯并咪唑用于治疗选自自身免疫性疾病、炎症性疾病、心血管疾病、神经退行性疾病、过敏、哮喘、胰腺炎、多器官衰竭、肾脏疾病、血小板聚集、癌症、精子活力、移植排斥、移植物排斥和肺损伤的疾病状态。特别是,本发明涉及用于治疗癌症的 PI3Kβ 选择性苯并咪唑类药物。